Richard M Wolf

Richard M Wolf serves as a Clinical Associate Professor within the Department of Clinical Sciences at the University of Illinois Urbana-Champaign, maintaining an active institutional email contact (wolf1@illinois.edu). His academic role centers on clinical sciences with a specialized focus on urologic malignancies, bridging laboratory techniques and patient care through extensive research in cancer diagnostics and treatment monitoring.

Dr. Wolf's research program demonstrates deep expertise in urologic oncology, particularly bladder and prostate cancer pathophysiology. He pioneered the application of flow cytometry for monitoring intravesical BCG therapy in bladder carcinoma and for nucleic acid analysis in bladder irrigation specimens. His work explores rare conditions like prostate angiosarcoma, investigating potential links with prior radiation therapy, and examines radiation-induced downstaging in bladder cancer management. These investigations position him at the critical intersection of surgical oncology, radiation therapy, and diagnostic cytology, with publications reflecting methodological rigor in translational cancer research.

Analysis of his publication trajectory from 1983 to 2012 reveals consistent innovation in flow cytometry applications for urologic cancers. Early work established cytometric techniques for cancer staging and treatment response assessment, while later research (2012) shifted toward rare prostate malignancies, conducting comprehensive case analyses and literature reviews to elucidate etiological factors. The interdisciplinary nature of his scholarship connects urology, radiation oncology, and molecular pathology, highlighting the evolution of diagnostic approaches in genitourinary cancers over three decades.

Scientific Awards:

• No awards, fellowships, or medals were documented in the source material.

Advising and Grants:

• No information regarding graduate students, postdoctoral trainees, or research funding mechanisms was provided in the available text.

Laboratory Affiliations:

• Research collaborations with Memorial Sloan Kettering Cancer Center investigators (evident from co-authorship patterns) suggest access to specialized urologic oncology facilities, though specific laboratory names were not disclosed.